New Anti-VEGF Agents Extend Dosing Intervals in Wet AMD
Table of Contents
Age-related macular degeneration (AMD) remains a leading cause of vision loss, and the advent of new anti-vascular endothelial growth factor (anti-VEGF) therapies has significantly altered the treatment paradigm. However, with increased options comes increased complexity. Recent discussions among leading ophthalmologists emphasize a personalized approach, carefully considering patient history and potential risks when selecting the most appropriate anti-VEGF agent. This article delves into the evolving strategies for treating exudative AMD, balancing efficacy, safety, and cost-effectiveness.
First-Line Choices: Established Efficacy and Biosimilar Opportunities
For many patients, first-generation anti-VEGFs – ranibizumab (Lucentis) and aflibercept 2 mg (Eylea) – continue to be excellent first-line treatment options. These agents boast well-established safety profiles and demonstrated efficacy in controlling neovascular AMD.
“First-generation anti-VEGFs still remain a good first-line treatment choice,” stated Dr. Mrejen during a recent session on exudative AMD. The availability of biosimilars for these drugs further enhances their appeal, offering a more affordable choice without compromising treatment quality. Ranibizumab biosimilars launched in 2023, with aflibercept biosimilars anticipated in 2026. This increased accessibility is crucial for broader patient reach.
Though, treatment response varies. Early in treatment,typically after 2-4 injections,some patients may experience intraocular inflammation – a phenomenon that requires careful monitoring. While this observation needs further confirmation in real-world practice with aflibercept 8 mg (Yezo), it highlights the importance of vigilant patient assessment.
When to Consider second-Generation Anti-VEGFs
While first-generation agents remain strong contenders, second-generation anti-VEGFs offer potential benefits for specific patient populations. If macular fluid control is suboptimal with initial treatment, or if extending the injection interval beyond two months proves difficult, switching to a more potent second-generation molecule may be warranted.Currently, the second-generation options include brolucizumab (Beovu), faricimab (Vabysmo), and aflibercept 8 mg. However, these agents aren’t created equal.Brolucizumab carries a less favorable safety profile and should be reserved for second-line treatment, notably in more severe cases of AMD.
Faricimab and aflibercept 8 mg are generally better tolerated,but are not recommended as first-line agents in patients with a history of intraocular inflammation. This underscores the critical importance of a thorough patient history before initiating treatment.
Managing Inflammation: A Precautionary Approach
Intraocular inflammation is a key concern with second-generation anti-VEGFs, ofen occurring during the induction phase – after the first two or three monthly injections. Open communication with patients is paramount, educating them about early warning signs such as pain, redness, or blurred vision, and emphasizing the need for urgent consultation if these symptoms arise.
The optimal course of action when inflammation occurs remains a topic of debate. Dr. Mrejen recommends switching back to a first-generation molecule once the inflammation resolves. Though, Dr. Streho suggests the decision should be tailored to the severity of the inflammation, acknowledging patient preferences regarding injection frequency.
Dr. Baillif, head of the Department of Ophthalmology at the Nice University Hospital, advocates for a precautionary principle: opting for better-tolerated molecules. In the case of inflammation under brolucizumab, switching to faricimab or aflibercept 8 mg may be considered, but the reverse is not advised.Ultimately, the selection and management of anti-VEGF therapies require a personalized approach, prioritizing patient safety and maximizing visual outcomes. Continued research and data collection are essential to refine treatment strategies and optimize care for individuals with exudative AMD.